ArticleAnaesthesia, critical care & pain medicine2021
National incidence rate and related mortality for acute respiratory distress syndrome in France.
Article in Anaesthesia, critical care & pain medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Nationwide trends in incidence and in-hospital mortality of ARDS in Germany, 2008-2022.Scientific reports · 2026Article
- Characteristics and prognosis of patients with cirrhosis presenting with acute respiratory distress syndrome: A bicentric retrospective study.Journal of intensive medicine · 2026Article
- Clinical Severity and Organ Dysfunction as Drivers of Mortality in Antimicrobial-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- A multilevel analysis of mortality and determinants among patients with acute respiratory distress syndrome in Ethiopia.Scientific reports · 2026Observational
- Rare genetic variant risks in patients with sepsis-associated acute respiratory distress syndrome.Respiratory research · 2026Article
- A prospective clinical evaluation of new ECCO2R technology in mild to moderate ARDS patients: assessing ultra-lung-protective ventilation with PRISMALUNG.Critical care (London, England) · 2026Article
- Polydatin in respiratory diseases: multi-target mechanisms and therapeutic potential.Frontiers in pharmacology · 2026Review
- A nomogram for predicting ARDS progression and need for invasive ventilation in COVID-19 patients using plasma hyaluronic acid and clinical scores.Frontiers in cellular and infection microbiology · 2026Article
- Eosinophil count combined with routine indicators enhances early risk prediction value for ARDS in ICU patients: a retrospective cohort study.Open medicine (Warsaw, Poland) · 2026Article
- A prediction model for 30-day mortality in patients with ARDS admitted to the intensive care unit.European journal of medical research · 2025Article
- Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies.Signal transduction and targeted therapy · 2025Review
- Prognostic impact of angiotensin-converting enzyme inhibitors and dexmedetomidine in acute respiratory distress syndrome: a MIMIC-IV-based retrospective cohort analysis.Frontiers in medicine · 2025Article
- Effects of ambient air pollutants on ARDS incidence and outcome: a narrative review.Annals of intensive care · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite many efforts to improve mechanical ventilation strategies and the use of rescue strategies, ARDS-related mortality remains high. The primary objective of this study was to determine the incidence and 90-day mortality of ARDS patients admitted to all French ICUs following the introduction of the Berlin definition of ARDS. PATIENTS AND
methodsThe data source for this nationwide cohort study was the French national hospital database (Programme de Médicalisation des Systèmes d'Information (PMSI)), which systematically collects administrative and medical information related to all patients hospitalised and hospital stays. Patient-level data were obtained from the PMSI database for all patients admitted to an ICU from the 1
resultsA total of 12,846 ICU adult patients with ARDS were included. The crude incidence of ARDS was 24.6 per 100,000 person-years, varying with age from 6.7 per 100,000 person-years for those 18 through 40 years of age to 51.9 per 100,000 person-years for those 68 through 76 years of age. The in-hospital mortality rate was 51.1%. Day-90 mortality (day-1 being the ICU admission) was 51.2% and increased with age from 29.0% for patients 18 through 40 years of age to 69.3% for patients 77 years of age or older (p < 0.001). Only 53.9% of the survivors were transferred home directly after hospital discharge.
conclusionsThe incidence and mortality of ARDS in adults in France are higher than that generally reported in other countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.